source
- Lycia Therapeutics raises $318 million in IPO to fund protein degrader programsLycia Therapeutics, a biotech focused on protein-degrading medicines, priced its initial public offering at about $318 million. The proceeds will be used to advance three LYTAC drug candidates, in…
- RNAi developers see surge in IPOs and funding as industry interest revivesBioPharma Dive’s latest data‑visualization series highlights a rapid rise in interest and investment for companies developing RNA interference (RNAi) medicines. After a years‑long lull, more than…